Apoptosis induced by β,β-dimethylacrylshikonin is associated with Bcl-2 and NF-κB in human breast carcinoma MCF-7 cells

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1789-1793

  Xiong, Yao ^a   Ma, Xiu Ying ^a   Zhang, Ziran ^b   Shao, Zhen Jun ^a   Zhang, Yuan Yuan ^a   Zhou, Li Ming ^a  

^a SICHUAN UNIVERSITY   (China)

^b Jinan Hongjitang Pharmaceutical Limited liability Company   (China)

Author keywords

, dimethylacrylshikonin; Apoptosis; Breast cancer; Nuclear factor B

Indexed keywords

ANTINEOPLASTIC AGENT; BETA,BETA DIMETHYLACRYLSHIKONIN; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA FRAGMENTATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84886794620     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1613     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974-984, 1998.
4. Chen X, Yang L, Zhang N, et al: Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 47: 2810-2816, 2003.
5. Mao X, Yu CR, Li WH and Li WX: Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 18: 879-888, 2008.
6. Yang H, Zhou P, Huang H, et al: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459, 2009.
7. Wu YY, Wan LH, Zheng XW, et al: Inhibitory effects of β, β-dimethylacrylshikonin on hepatocellular carcinoma in vitro and in vivo. Phytother Res 26: 764-771, 2012.
8. Pietrosiuk A, Furmanowa M, Skopińiska-Rózewska E, et al: The effect of acetylshikonin isolated from Lithospermum canescens roots on tumor-induced cutaneous angiogenesis. Acta Pol Pharm 61: 379-382, 2004.
9. Gong K and Li W: Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma. Free Radic Biol Med 51: 2259-2271, 2011.
10. Kim SH, Kang IC, Yoon TJ, et al: Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett 172: 171-175, 2001.
11. Litchfield JT Jr and Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-113, 1949.
12. Zeng Y, Liu G and Zhou LM: Inhibitory effect of acetylshikonin on human gastric carcinoma cell line SGC-7901 in vitro and in vivo. World J Gastroenterol 15: 1816-1820, 2009.
13. Chen X, Yang L, Oppenheim JJ and Howard MZ: Cellular pharmacology studies of shikonin derivatives. Phytother Res 16: 199-209, 2002.
14. Lu L, Qin A, Huang H, et al: Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol 658: 242-247, 2011.
15. Sankawa U, Ebizuka Y, Miyazaki T, et al: Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo) 25: 2392-2395, 1977.
16. Yoshimi N, Wang A, Morishita Y, et al: Modifying effects of fungal and herb metabolites on azoxymethane-induced intestinal carcinogenesis in rats. Jpn J Cancer Res 83: 1273-1278, 1992.
17. Ahn BZ, Baik KU, Kweon GR, et al: Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem 38: 1044-1047, 1995.
18. Plyta ZF, Li T, Papageorgiou VP, et al: Inhibition of topoisomerase I by naphthoquinone derivatives. Bioorg Med Chem Lett 8: 3385-3390, 1998.
19. Yang F, Chen Y, Duan W, et al: SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer 119: 1184-1193, 2006.
20. Gaddipati JP, Mani H, Shefali, et al: Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA). Anticancer Res 20: 2547-2552, 2000.
21. Chang IC, Huang YJ, Chiang TI, et al: Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells. Biol Pharm Bull 33: 816-824, 2010.
22. Zhen-Jun S, Yuan-Yuan Z, Ying-Ying F, et al: β, β-Dimethylacrylshikonin exerts antitumor activity via Notch-1 signaling pathway in vitro and in vivo. Biochem Pharmacol 84: 507-512, 2012.
23. Green DR and Evan GI: A matter of life and death. Cancer Cell 1: 19-30, 2002.
24. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
25. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
26. Shen HM and Tergaonkar V: NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14: 348-363, 2009.
27. Tergaonkar V, Correa RG, Ikawa M and Verma IM: Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nat Cell Biol 7: 921-923, 2005.
28. Basak S, Kim H, Kearns JD, et al: A fourth IκB protein within the NF-κB signaling module. Cell 128: 369-381, 2007.